Establishment of Mthera

Registration of R&D Center

1st VC Funding

Venture Business Certification (Korea Venture Capital Association)

Certified as ‘Outstanding Company of Technological Capability’ (Korea Enterprise Data Co.)

Opening of Magok R&D Center

Selected as TIPS (Tech Incubator Program for Startup) Partners

2nd VC Funding

SI Investment

Received ‘2020 Technical Innovation Enterprise Award’ (Hankookilbo, Sponsored by Ministry of SMEs and Startups & and Ministry of Trade, Industry and Energy)

Received ‘Korea Industry Award First-in-class Award’ (MONEYTODAY, Sponsored by Ministry of Trade, Industry and Energy/Ministry of Environment/ Ministry of Education)

Selected R&D achievement: Outstanding Achievement 100 (Platform on Science and Technology Policy for Social Problem Solving(Ministry of Science and ICT))

Initiation of P1 SAD study for MT101 (Parkinson’s Disease treatment)

63 Patents Filed, 14 Patents Granted (Domestic & International)

Received ‘2022 16th Korea Excellent Patent Award(Bioscience and Biotechnology)’ (Hankookilbo, Sponsored by Korea Institute of Patent Information)

Article published on MT101 (‘Inhibition of α-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson’s disease’, Biomed Pharmacother. 2022)

GC Wellbeing’s cancer cachexia treatment candidate licensed out to Mthera Pharma with co-development agreement

Received 6th Korea’s Nobel Science Awards ‘Science Technology Creation Award’

Agri-food Products R&D Technical Commercialization Excellence Award (Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry)

BIOTECH SHOWCASE 2023 MTHERA PHARMA company presentation (Hilton San Francisco Union Square)

Received the Highest Grade(S) of the Final Evaluation from NRF(National Research Foundation of Korea) Bio & Medical Technology Development Program

SAB agreement with professor Seeram of Rhode Island University

MOU agreement with the NEMIC Foundation

MT101 (Parkinson’s disease treatment) US Phase 1 clinical trial complete, initiation of Phase 2 clinical trial scheduled for 2H 2023

58 patents filed, 20 patents granted (Domestic & International)